{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory+ALL&page=73",
    "query": {
      "condition": "Relapsed/Refractory ALL",
      "page": 73
    },
    "page_size": 10
  },
  "pagination": {
    "page": 73,
    "page_size": 10,
    "total_count": 3667,
    "total_pages": 367,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory+ALL&page=74&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory+ALL&page=72&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-18T02:44:25.703Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01588821",
      "title": "Cabozantinib in Advanced Solid Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer",
        "Solid Tumor (Not Breast or Prostate Cancers)"
      ],
      "interventions": [
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2012-06",
      "completion_date": "2019-06",
      "has_results": true,
      "last_update_posted_date": "2020-09-29",
      "last_synced_at": "2026-11-18T02:44:25.703Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01588821"
    },
    {
      "nct_id": "NCT04075721",
      "title": "First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "M3258",
          "type": "DRUG"
        },
        {
          "name": "M3258 20 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono Research & Development Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2019-09-26",
      "completion_date": "2021-04-01",
      "has_results": true,
      "last_update_posted_date": "2023-03-24",
      "last_synced_at": "2026-11-18T02:44:25.703Z",
      "location_count": 4,
      "location_summary": "Denver, Colorado • Washington D.C., District of Columbia • Hackensack, New Jersey + 1 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04075721"
    },
    {
      "nct_id": "NCT06792734",
      "title": "Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma, B-Cell"
      ],
      "interventions": [
        {
          "name": "BTM-3566",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bantam Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2025-02-14",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-07",
      "last_synced_at": "2026-11-18T02:44:25.703Z",
      "location_count": 2,
      "location_summary": "Charlotte, North Carolina • Houston, Texas",
      "locations": [
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06792734"
    },
    {
      "nct_id": "NCT07513181",
      "title": "Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ulcerative Colitis",
        "Inflammatory Bowel Diseases",
        "Autoimmune Diseases"
      ],
      "interventions": [
        {
          "name": "ATH-063",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Athos Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 120,
      "start_date": "2026-04-30",
      "completion_date": "2028-12-14",
      "has_results": false,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-11-18T02:44:25.703Z",
      "location_count": 4,
      "location_summary": "Miami, Florida • Tampa, Florida • Roswell, Georgia + 1 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Roswell",
          "state": "Georgia"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07513181"
    },
    {
      "nct_id": "NCT02464228",
      "title": "Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Relapsed or Refractory Peripheral T-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Tipifarnib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kura Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 65,
      "start_date": "2016-02-25",
      "completion_date": "2021-03-31",
      "has_results": true,
      "last_update_posted_date": "2024-06-26",
      "last_synced_at": "2026-11-18T02:44:25.703Z",
      "location_count": 5,
      "location_summary": "Palo Alto, California • New Haven, Connecticut • Tampa, Florida + 2 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02464228"
    },
    {
      "nct_id": "NCT03393611",
      "title": "CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myelodysplastic Syndromes",
        "Leukemia, Myeloid, Acute",
        "Leukemia, Relapsed Adult Acute Myeloid",
        "Myelodysplastic Syndromes, Previously Treated"
      ],
      "interventions": [
        {
          "name": "CPX-351",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Rabbit Anti-Human T-Lymphocyte Globulin",
          "type": "DRUG"
        },
        {
          "name": "Haplo-Cord Stem Cell Transplantation",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 14,
      "start_date": "2012-11-30",
      "completion_date": "2021-11-18",
      "has_results": false,
      "last_update_posted_date": "2022-12-21",
      "last_synced_at": "2026-11-18T02:44:25.703Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03393611"
    },
    {
      "nct_id": "NCT04882163",
      "title": "Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma, B-Cell"
      ],
      "interventions": [
        {
          "name": "CC-220",
          "type": "DRUG"
        },
        {
          "name": "Polatuzumab vedotin",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Tafasitamab",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Bendamustine",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2021-10-10",
      "completion_date": "2029-04-07",
      "has_results": false,
      "last_update_posted_date": "2021-10-05",
      "last_synced_at": "2026-11-18T02:44:25.703Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Ann Arbor, Michigan • Sioux Falls, South Dakota",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Sioux Falls",
          "state": "South Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04882163"
    },
    {
      "nct_id": "NCT00588809",
      "title": "Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)",
        "Adult Acute Promyelocytic Leukemia (M3)",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasms",
        "Recurrent Adult Acute Myeloid Leukemia",
        "Secondary Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "selumetinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2007-12",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2015-08-05",
      "last_synced_at": "2026-11-18T02:44:25.703Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00588809"
    },
    {
      "nct_id": "NCT04150328",
      "title": "Lenalidomide Monotherapy in R/R DLBCL",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diffuse Large B Cell Lymphoma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "MorphoSys AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 490,
      "start_date": "2019-04-12",
      "completion_date": "2020-08-25",
      "has_results": false,
      "last_update_posted_date": "2022-08-24",
      "last_synced_at": "2026-11-18T02:44:25.703Z",
      "location_count": 8,
      "location_summary": "Rochester, Minnesota • St Louis, Missouri • Manhasset, New York + 5 more",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Manhasset",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04150328"
    },
    {
      "nct_id": "NCT00241371",
      "title": "A Phase II Study of Clofarabine in Patients With Relapsed or Refractory Multiple Myeloma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Clofarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2005-03",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2013-08-13",
      "last_synced_at": "2026-11-18T02:44:25.703Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00241371"
    }
  ]
}